106.17
前日終値:
$106.10
開ける:
$106.03
24時間の取引高:
1.06M
Relative Volume:
0.32
時価総額:
$9.18B
収益:
-
当期純損益:
$-153.72M
株価収益率:
-53.09
EPS:
-2
ネットキャッシュフロー:
$-103.81M
1週間 パフォーマンス:
+0.37%
1か月 パフォーマンス:
+0.94%
6か月 パフォーマンス:
+60.94%
1年 パフォーマンス:
+290.19%
Verona Pharma Plc Adr Stock (VRNA) Company Profile
名前
Verona Pharma Plc Adr
セクター
電話
011-44-0-2032834200
住所
3 MORE LONDON RIVERSIDE, LONDON
VRNA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VRNA
Verona Pharma Plc Adr
|
106.17 | 9.18B | 0 | -153.72M | -103.81M | -2.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.62 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.80 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
447.43 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
722.01 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
336.26 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2025-07-01 | 開始されました | Wolfe Research | Outperform |
2025-04-28 | 開始されました | TD Cowen | Buy |
2025-04-21 | 開始されました | Cantor Fitzgerald | Overweight |
2025-01-10 | 開始されました | ROTH MKM | Buy |
2024-10-03 | 開始されました | Wells Fargo | Overweight |
2023-05-22 | 再開されました | Jefferies | Buy |
2022-09-19 | 再開されました | Wedbush | Outperform |
2022-08-26 | 開始されました | Piper Sandler | Overweight |
2021-09-13 | 開始されました | H.C. Wainwright | Buy |
2020-08-25 | 開始されました | Jefferies | Buy |
2020-08-10 | 開始されました | Canaccord Genuity | Buy |
2019-04-18 | 開始されました | BTIG Research | Buy |
すべてを表示
Verona Pharma Plc Adr (VRNA) 最新ニュース
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Verona Pharma stock hits all-time high at 105.86 USD By Investing.com - Investing.com Australia
Verona Pharma stock hits all-time high at 105.86 USD - Investing.com
TRAILBLAZERS TAKE THE STAGE: PM360 TO CROWN LIFE SCIENCES' BRIGHTEST, SEPTEMBER 30 - Seeking Alpha
Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck - MSN
Verona Pharma : Notice of Meetings and Proxy Statement in connection with proposed acquisition of Verona Pharma - MarketScreener
Verona Pharma stock reaches all-time high at 105.54 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock reaches all-time high at 105.54 USD - Investing.com
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Verona Pharma ADR earnings beat by $0.11, revenue topped estimates - Investing.com Nigeria
Verona Pharma CFO Hahn sells $2.75 million in shares By Investing.com - Investing.com India
Verona Pharma (VRNA) director Ackermann sells $24k in shares - Investing.com
Verona Pharma CFO Hahn sells $2.75 million in shares - Investing.com
Verona Pharma director Cunningham sells shares for $142,057 By Investing.com - Investing.com South Africa
Verona Pharma (VRNA) director Deschamps sells $124,391 in shares - Investing.com India
Verona Pharma director Cunningham sells shares for $142,057 - Investing.com India
VERONA PHARMA PLCADR: Quantitative Momentum Investor Model Ratings - AInvest
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com Australia
Verona Pharma stock reaches all-time high at 105.0 USD - Investing.com
Weathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA Now - Yahoo Finance
Pharmaceutical Stocks To Research – July 12th - Defense World
Top Medical Stocks To Follow Now – July 12th - Defense World
Wells Fargo Downgrades Verona Pharma plcDepositary Receipt () (VRNA) - MSN
Merck stock rises as UBS reiterates Buy rating after Verona Pharma acquisition By Investing.com - Investing.com South Africa
Merck to acquire Verona Pharma stock for $107 per ADS in $10 billion deal By Investing.com - Investing.com South Africa
Verona Pharma stock rating downgraded to Neutral by Roth/MKM after Merck offer - Investing.com South Africa
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact - Mitrade
Verona Pharma stock hits all-time high at 104.83 USD By Investing.com - Investing.com South Africa
American pharmaceutical company Merck acquires British Verona Pharma for $10 billion - AKM.RU
Verona Pharma stock hits all-time high at 104.83 USD - Investing.com
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
Merck to acquire Verona Pharma for $10 billion By Investing.com - Investing.com Nigeria
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck to acquire Verona Pharma for $10 billion - Investing.com Australia
Can Verona Pharma Plc ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Starbucks, Freeport-McMoran and Verona Pharma rise premarket; WPP, T-Mobile fall By Investing.com - Investing.com South Africa
Merck compra por 10.000 millones de dólares Verona Pharma - Yahoo Finanzas
Best Momentum Stock To Buy For July 7th - Barchart.com
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - Yahoo Finance
Up 515%, Watch This Biopharma Breakout - inkl
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
Piper Sandler reiterates Verona Pharma stock rating and target By Investing.com - Investing.com UK
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Verona Pharma (VRNA) Shares Soar 5.47% to Record High - AInvest
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma Plc Adr (VRNA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):